Acute hepatitis B in the vaccination era: Predictors of functional cure and chronicity

doi:10.4254/wjh.124108

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

(2)

(3)

(0)

(1)

(48)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Aug 27, 2026; 18(8): 124108
Published online Aug 27, 2026. doi: 10.4254/wjh.124108

Table 1 Patient characteristics, n (%) or mean ± SD

	Total (n = 78)	Chronic HBV (n = 27)	Functional cure (n = 51)	P value¹
Male	55 (71)	23 (85)	32 (63)	0.03
Ethnicity				0.3
Arab	20 (26)	9(33)	11 (22)
Jewish	58 (74)	18 (67)	40 (78)
Age (years)	39.2 ± 15.5	42.0 ± 17.2	37.7 ± 14.6	0.3
Region of birth				0.4
Israel	48 (62)	16 (59)	32 (63)
Africa	8 (10)	5 (19)	3(5.9)
Middle East	7 (9)	3 (11)	4 (7.8)
Russia/Former Union of Soviet Socialist Republics	8 (10)	1 (3.7)	7 (14)
Europe	2 (2.6)	1 (3.7)	1 (2)
Other	5 (6.4)	1 (3.7)	4 (7.8)
History of alcohol use	7 (9)	2 (7.4)	5 (9.8)	> 0.9
Active smoking	8 (16)	2 (15)	6 (17)	0.3
IV drug use	5 (6.4)	2 (7.4)	3 (5.9)	> 0.9
BMI (kg/m²)	25.4 ± 7.1	26.7 ± 6.1	24.7 ± 7.5	0.2
Diabetes mellitus	9 (12)	7 (26)	2 (3.9)	0.007
Hypertension	17 (22)	7 (26)	10 (20)	0.5
Dyslipidemia	5 (6.4)	3 (11)	2 (3.9)	0.3
Anti-HBs positive	30 (48)	8 (33)	22 (58)	0.059
HBeAg positive	49 (64)	18 (67)	31 (62)	0.7
HBV DNA (IU/mL)²	1.48 × 10⁶ ± 3.5 × 10⁶	1.25 × 10⁶ ± 9.2 × 10⁵	1.54 × 10⁶ ± 3.9 × 10⁶	0.8

¹Pearson’s χ² test; Wilcoxon rank sum test.

²Data available for only 25.9% and 58.8% of patients in the chronic hepatitis B virus and functional cure groups respectively.

HBV: Hepatitis B virus; BMI: Body mass index; HBeAg: Hepatitis B envelope antigen; Anti-HBs: Anti-hepatitis B surface.

Full Size Table

Citation: Yardeni D, Gershbaum Tobin J, Itkowitz B, Lipnizkiy I, Abu Juma’a A, Abu-Freha N, Keren-Naus A, Turgeman M, Nevo-Shor A, Gish RG, Etzion O. Acute hepatitis B in the vaccination era: Predictors of functional cure and chronicity. World J Hepatol 2026; 18(8): 124108
URL: https://www.wjgnet.com/1948-5182/full/v18/i8/124108.htm
DOI: https://dx.doi.org/10.4254/wjh.124108

Yardeni D, Gershbaum Tobin J, Itkowitz B, Lipnizkiy I, Abu Juma’a A, Abu-Freha N, Keren-Naus A, Turgeman M, Nevo-Shor A, Gish RG, Etzion O. Acute hepatitis B in the vaccination era: Predictors of functional cure and chronicity. World J Hepatol 2026; 18(8): 124108 [DOI: 10.4254/wjh.124108]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.